CDR-Life develops antibody therapeutics targeting intracellular proteins presented on the major histocompatibility complex (MHC). The company uses its M-gager® technology to generate MHC-specific antibody-based T cell engagers for tumor-specific intracellular antigens.

CDR-Life

Campus Biotech is an interdisciplinary center dedicated to neuroscience and digital and global health. It aims to transform innovation into medical advancements.

Campus Biotech

CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We are leveraging this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface tumor antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to eliminate tumors.

CDR-Life Inc.

Honored to be recognized by Labiotech.eu as a Swiss biotech to watch! Curious about our innovative T-cell engagers? Discover how we're harnessing the immune system to fight cancer at www.cdr-life.com.

A pleasure to present results in our joint poster with Boehringer Ingelheim at ARVO. Together we are working to bring a much-needed treatment option to the millions of patients who are living with geographic atrophy disease. #ARVO2024

Great news! CDR-Life Inc. expands its innovative cancer therapy portfolio with the addition of two highly tumor-targeted T cell engagers (TCE):
 
- CDR813: A powerhouse T cell engager targeting PRAME in HLA-A*02:01 patients. PRAME is a clinically validated pan-cancer target expressed in a broad set of tumors including non-small cell lung cancer, endometrial cancer, melanoma and ovarian cancer but not in normal tissue. This bi-valent, bi-specific antibody shows unparalleled potency and precision.
- CDR505: Breaking new ground with a T cell engager for KK-LC-1 in HLA-A01 patients. This expands treatment possibilities beyond the common HLA-A02 focus to benefit a large patient population with high unmet need.

These additions strengthen CDR-Life's mission to develop targeted cancer therapies for broader patient populations. Read more: https://bit.ly/4bldGNA

CDR-Life CEO Christian Leisner spoke with Drug Discovery World about methods for increasing access to antigens and improving immunotherapy treatments. Read the full article here: https://lnkd.in/e-gYrXKm

We are thrilled to announce the initiation of enrollment for the Phase 1 trial of CDR404, our lead program in development as a precision immunotherapy for solid tumors. The study was published as an online presentation at #ASCO24
Based on the company’s unique M-gager® technology, CDR404 is a first-of-its-kind, antibody-based bivalent and bispecific MAGE-A4 T-cell engager (TCE) for the treatment of MAGE-A4 positive solid tumors. The Phase I study evaluating CDR404 is actively enrolling at sites in the U.S. and Europe. 

Read more: https://bit.ly/3UT8GcQ

Great article in SCRIP where CDR-Life CEO Christian Leisner details his predictions on the role that T-cell engagers will play in the development of solid tumor therapies: https://bit.ly/4bAjTXs

Metric
Company Name	CDR-Life	Campus Biotech
Symbol
MSH ID	COM:CDR-LIFE	CH:CAMPUSBIOTECH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Life Sciences
Country	CH	CH
Stage
Employee Count	69
Website	cdr-life.com	campusbiotech.ch
LinkedIn	cdr-life-inc-	campus-biotech
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.59
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CDR-LIFE

CDR-Life

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue